Tech Company Financing Transactions
LyGenesis Funding Round
On 10/24/2023, LyGenesis raised $19 million in Series A funding from Prime Movers Lab and Juvenescence.
Transaction Overview
Company Name
Announced On
10/24/2023
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series A
Investors
Prime Movers Lab (Lead Investor)
Juvenescence (Gregory Bailey)
Proceeds Purpose
The company intends to use the funds to complete its Phase 2a clinical trial (ClinicalTrials.gov Identifier: NCT04496479) and advance its pipeline of cell therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2730 Sidney St. 300
Pittsburgh, PA 15203
USA
Pittsburgh, PA 15203
USA
Phone
Undisclosed
Website
Email Address
Overview
LyGenesis, Inc. is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Our initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Hufford
Chief Medical Officer
Paulo Fontes
Chief Scientific Officer
Eric Lagasse
Browse more venture capital transactions:
Prev: 10/24/2023: Rhizome venture capital transaction
Next: 10/24/2023: JourneyTrack venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs